The VGF-derived neuropeptide TLQP-62 rapidly reversed depression-like behavior in mice by activating the same TrkB/mTOR signaling pathway used by ketamine.
Rapid antidepressant effect via TrkB/mTOR pathwayTLQP-62 activated the same brain signaling cascade that makes ketamine a fast-acting antidepressant — but through the brain's own neuropeptide system rather than an external drug.
What the researchers found
The neuropeptide fragment TLQP-62, derived from the VGF protein, produced rapid antidepressant-like effects when administered directly into the prefrontal cortex of mice. It also reversed depression-like behaviors caused by chronic social defeat stress — a validated mouse model of depression.
The mechanism was traced to a specific signaling cascade: TLQP-62 activates the TrkB receptor (the BDNF receptor), which triggers mTOR signaling, decreases the gene BICC1, and increases synaptic proteins including the AMPA receptor GluA1 subunit. When researchers blocked TrkB with the antagonist ANA-12, all of TLQP-62's antidepressant effects were abolished — confirming TrkB as the essential starting point of the cascade.
Why it matters
Most antidepressants take weeks to work. TLQP-62 produces rapid antidepressant effects through a pathway that overlaps with ketamine's mechanism (TrkB/mTOR/synaptic protein synthesis). This suggests VGF-derived peptides could represent a new class of fast-acting antidepressants that work through the brain's own neurotrophic system rather than targeting serotonin or other monoamines.
The numbers in context
TLQP-62 infused into PFC · Rapid antidepressant effects · Reversed CSDS-induced depression · TrkB/mTOR/BICC1 signaling pathway · GluA1 phosphorylation at Ser845 · Effects abolished by TrkB antagonist ANA-12
How the study worked
Mouse study using two depression models: acute behavioral tests and chronic social defeat stress (CSDS). TLQP-62 was administered directly into the prefrontal cortex. Researchers measured behavioral outcomes, signaling proteins (TrkB, mTOR, BICC1, GluA1), and phosphorylation states. The TrkB antagonist ANA-12 was used to confirm mechanism specificity.
Who was studied
Male C57BL/6J mice in acute and chronic social defeat stress models
What this study cannot tell us
Animal study only — no human data. TLQP-62 was delivered directly into the brain, which isn't a viable clinical route. The peptide's ability to cross the blood-brain barrier from systemic administration is unknown. Male mice only. The chronic social defeat stress model, while validated, doesn't fully capture human depression.
How to read the evidence
Rated low: well-designed animal mechanistic study with clear pathway delineation, but no human data. Direct brain injection limits translational relevance. Male mice only.
When this study was published
Published in 2018. VGF-derived peptide research has continued to expand, with ongoing investigation into their antidepressant potential and delivery challenges.
The bigger picture
The discovery that ketamine produces rapid antidepressant effects through TrkB/mTOR signaling revolutionized depression research. TLQP-62 appears to tap into this same pathway but through the brain's own neuropeptide system. If VGF-derived peptides can be made to reach the brain from a practical route of administration, they could offer rapid antidepressant effects without ketamine's dissociative side effects and abuse potential.
Questions still open
- Can TLQP-62 or similar VGF-derived peptides cross the blood-brain barrier when given systemically?
- How do the antidepressant effects of TLQP-62 compare to ketamine in head-to-head studies?
- Are VGF peptide levels altered in people with depression, and could they serve as biomarkers?
Common questions
What is TLQP-62 and how does it fight depression?
Could TLQP-62 become an antidepressant medication?
Read the original research
Mechanisms underlying the rapid-acting antidepressant-like effects of neuropeptide VGF (non-acronymic) C-terminal peptide TLQP-62.
Neuropharmacology, 143, 317-326
Citation
Lv, Dan; Chen, Yaping; Shen, Mengxin; Liu, Xu; Zhang, Yanhua; Xu, Jiangping; Wang, Chuang. (2018). Mechanisms underlying the rapid-acting antidepressant-like effects of neuropeptide VGF (non-acronymic) C-terminal peptide TLQP-62.. Neuropharmacology, 143, 317-326. https://doi.org/10.1016/j.neuropharm.2018.09.046